- Company
- What's the outcome of the 2nd reimb attempt for 'Uplizna'?
- by Eo, Yun-Ho Nov 17, 2025 06:11am
- Attention has been drawn to whether 'Uplizna,' a new treatment for neuromyelitis optica spectrum disorders (NMOSD), will successfully gain insurance reimbursement listing at its second attempt. According to industry sources, Mitsubishi Tanabe Pharma Korea has accepted the conditional price that Health Insurance Review and Assessment Servic
- Company
- Generic companies win 1st trial on unlisted Jardiance patent
- by Kim, Jin-Gu Nov 17, 2025 06:10am
- Generic drugmakers have scored the first victory in Korea’s ongoing disputes over unlisted patents related to the SGLT-2 inhibitor class diabetes treatment Jardiance (empagliflozin). Industry observers expect this decision to set the tone for similar disputes surrounding Jardiance's unregistered patents that are pending. According to ind
- Company
- "Expanded access to Pergoveris…for older infertile women"
- by Son, Hyung Min Nov 14, 2025 06:12am
- The paradigm of infertility treatment is shifting amid the increased age of mothers and the expansion of the patient population with poor ovarian response (POR). Notably, the utilization of FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone) combination therapy has surged since the reimbursement criteria for 'Pergoveris inj (folli
- Company
- Generic company challenges flu drug Xofluza’s patent
- by Kim, Jin-Gu Nov 14, 2025 06:12am
- Roche's influenza treatment Xofluza (baloxavir marboxil) has become a generic company’s target for patent challenge. This marks the first patent challenge against Xofluza. Industry observers predict related patent challenges will continue in the near future. According to industry sources on the 13th, Kwangdong Pharmaceutical recently fil
- Company
- AZ runs Lung Health Check Bus…screens Changwon residents
- by Son, Hyung Min Nov 14, 2025 06:11am
- AstraZeneca Korea announced on the 12th that it operated a ‘Lung Health Check Bus’ equipped with AI-based chest X-ray technology at the ‘2025 Anti-Aging BIOHealth Expo (ABEXPO 2025)’, which was held at the Changwon Exhibition and Convention Center (CECO) in Gyeongsangnam-do from the 6th to the 8th, in collaboration with the Korea Tubercul
- Company
- "Life-cycle prevention system completed with Prevenar 20"
- by Son, Hyung Min Nov 13, 2025 06:07am
- "As pneumococcal infections occur in both adults and children, the need to establish a full-life-cycle prevention is growing. Especially given the high mortality rates in children, the elderly, and chronic disease patients, prevention-centered management is considered important. With the recent launch of 'Prevenar 20,' the 20-valent pneumococcal
- Company
- Former AZ Director Do to lead New Business at Lilly Korea
- by Eo, Yun-Ho Nov 13, 2025 06:07am
- Former AstraZeneca Commercial Director David H. Do (39) has taken on a new leadership role at Lilly Korea. According to industry sources, Lilly Korea recently appointed AZ Commercial Director Do to lead its newly launched Neurology Business Division. . As a result, Director Do will oversee sales and marketing for Lilly's neurology produ
- Company
- UCB Korea appoints Edward Lee as new GM
- by Son, Hyung Min Nov 13, 2025 06:07am
- UCB Korea announced that Edward Lee has been appointed as its new General Manager, effective November 1. Edward Lee is an expert with over 15 years of experience in the global pharmaceutical industry, in areas ranging from Market Access, Medical Affairs, to Health Economics & Outcomes Research (HEOR). Lee has a strong background in drivin
- Company
- Korea’s bio-industry production hits ₩22.9 trillion
- by Kim, Jin-Gu Nov 12, 2025 06:19am
- Last year, the domestic bio industry's production scale reached KRW 22.9216 trillion, a 9.8% increase compared to the previous year. Exports rose 17.1% year-on-year, driven by existing key export items such as antibody drugs and CMO for biopharmaceuticals. R&D investment increased by 3.2%. The Ministry of Trade, Industry and Energy, in co
- Company
- Biotech firms with net loss overestimate their performance
- by Cha, Jihyun Nov 12, 2025 06:19am
- While Korean biotech and healthcare companies are using the Technology Exception Listing system to challenge the Initial Public Offering (IPO) market, there have been concerns over their valuation methods. Critics argue that some companies are excessively inflating their valuations by presenting overly optimistic estimates of future performance
